Logo image of CRXT

CLARUS THERAPEUTICS HOLDINGS (CRXT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CRXT - US18271L1070 - Common Stock

0.099 USD
-0.06 (-36.94%)
Last: 8/30/2022, 8:05:42 PM
0.101 USD
+0 (+2.02%)
After Hours: 8/30/2022, 8:05:42 PM
Fundamental Rating

2

Overall CRXT gets a fundamental rating of 2 out of 10. We evaluated CRXT against 190 industry peers in the Pharmaceuticals industry. The financial health of CRXT is average, but there are quite some concerns on its profitability. CRXT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year CRXT has reported negative net income.
CRXT Yearly Net Income VS EBIT VS OCF VS FCFCRXT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 0 -10M -20M -30M -40M

1.2 Ratios

Industry RankSector Rank
ROA -66.68%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRXT Yearly ROA, ROE, ROICCRXT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 0 200 -200 -400

1.3 Margins

Industry RankSector Rank
OM -235.99%
PM (TTM) -193%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRXT Yearly Profit, Operating, Gross MarginsCRXT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 0 -200 -400 -600

More info and screens

4

2. Health

2.1 Basic Checks

  • CRXT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CRXT has about the same amount of shares outstanding.
  • Compared to 1 year ago, CRXT has an improved debt to assets ratio.
CRXT Yearly Shares OutstandingCRXT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 5M 10M 15M 20M
CRXT Yearly Total Debt VS Total AssetsCRXT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

  • CRXT has an Altman-Z score of -11.36. This is a bad value and indicates that CRXT is not financially healthy and even has some risk of bankruptcy.
  • There is no outstanding debt for CRXT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.36
ROIC/WACCN/A
WACC6.15%
CRXT Yearly LT Debt VS Equity VS FCFCRXT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 0 50M -50M -100M

2.3 Liquidity

  • A Current Ratio of 0.79 indicates that CRXT may have some problems paying its short term obligations.
  • A Quick Ratio of 0.52 indicates that CRXT may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.79
Quick Ratio 0.52
CRXT Yearly Current Assets VS Current LiabilitesCRXT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 43.66% over the past year.
  • Looking at the last year, CRXT shows a very strong growth in Revenue. The Revenue has grown by 39.87%.
EPS 1Y (TTM)43.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.34%
Revenue 1Y (TTM)39.87%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-20.73%

3.2 Future

  • Based on estimates for the next years, CRXT will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.39% on average per year.
  • Based on estimates for the next years, CRXT will show a very strong growth in Revenue. The Revenue will grow by 57.00% on average per year.
EPS Next Y87.39%
EPS Next 2Y39.54%
EPS Next 3Y25.66%
EPS Next 5Y14.39%
Revenue Next Year35.11%
Revenue Next 2Y52.3%
Revenue Next 3Y53.57%
Revenue Next 5Y57%

3.3 Evolution

CRXT Yearly Revenue VS EstimatesCRXT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
CRXT Yearly EPS VS EstimatesCRXT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -2 -4 -6 -8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • CRXT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRXT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRXT Price Earnings VS Forward Price EarningsCRXT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRXT Per share dataCRXT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

  • CRXT's earnings are expected to grow with 25.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.54%
EPS Next 3Y25.66%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for CRXT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLARUS THERAPEUTICS HOLDINGS / CRXT FAQ

What is the fundamental rating for CRXT stock?

ChartMill assigns a fundamental rating of 2 / 10 to CRXT.


Can you provide the valuation status for CLARUS THERAPEUTICS HOLDINGS?

ChartMill assigns a valuation rating of 0 / 10 to CLARUS THERAPEUTICS HOLDINGS (CRXT). This can be considered as Overvalued.


How profitable is CLARUS THERAPEUTICS HOLDINGS (CRXT) stock?

CLARUS THERAPEUTICS HOLDINGS (CRXT) has a profitability rating of 1 / 10.


What is the expected EPS growth for CLARUS THERAPEUTICS HOLDINGS (CRXT) stock?

The Earnings per Share (EPS) of CLARUS THERAPEUTICS HOLDINGS (CRXT) is expected to grow by 87.39% in the next year.